Vaccine with or without immunotherapy after standard treatment for brain cancer
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests adding a vaccine (UCPVax) with or without the immunotherapy drug pembrolizumab to standard chemotherapy after initial treatment. The goal is to see if these extra treatments can help prevent the brain tumor from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with glioblastoma (a type of brain tumor) that is IDH-wildtype and has unmethylated MGMT (a marker that can affect treatment).
- You have already completed the first part of standard treatment — radiation and temozolomide (chemotherapy) — and are ready to start follow-up chemo.
- You are in good physical condition (a performance score of at least 70%, meaning you can do most daily activities).
- Any steroids you take for brain swelling must be a low dose and stable for two weeks.
- You have not had treatment with drugs like bevacizumab (Avastin) or checkpoint inhibitors (like pembrolizumab) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine made from your own tumor cells, given after standard treatment (surgery and chemo/radiation) for newly diagnosed glioblastoma. The vaccine aims to train your immune system to fight any remaining cancer cells.
This trial tests an experimental vaccine for glioblastoma, given after the usual radiation and chemotherapy (temozolomide). The goal is to see if the vaccine helps the immune system fight remaining cancer cells.
This early-stage study tests a personalized cancer vaccine designed to prevent glioblastoma (a serious brain tumor) from coming back after surgery and standard treatment. The vaccine aims to train your immune system to recognize and attack any remaining cancer cells.
This trial tests a new immunotherapy that targets the CMV virus inside your glioblastoma tumor. It is for people who have already completed standard radiation and chemotherapy.
This trial tests giving the immunotherapy drug ipilimumab before the usual treatment for newly diagnosed glioblastoma (a type of brain cancer). The goal is to see if this approach is safe and possible, and whether it might help the immune system fight the tumor better.
This trial tests combining an immunotherapy drug (adebrelimab) with the standard chemotherapy temozolomide, with or without hyperbaric oxygen treatment, for patients with newly diagnosed glioblastoma who have already completed standard radiation and chemotherapy. The goal is to see if this combination can improve outcomes.
Hear when a new Primary Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.